The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer

[1]  H. Kuerer,et al.  Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. , 2015, Journal of the National Cancer Institute.

[2]  E. Gontier,et al.  18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer , 2015, The Journal of Nuclear Medicine.

[3]  W. Woodward,et al.  Circulating tumor cells in newly diagnosed inflammatory breast cancer , 2015, Breast Cancer Research.

[4]  J. Bonneterre,et al.  Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data , 2014, Clinical Cancer Research.

[5]  Isabelle Bedrosian,et al.  Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Bellon,et al.  Metabolic characterization of inflammatory breast cancer (IBC) with baseline FDG-PET/CT: Relationship with histopathology, hormone receptor status, and pathologic response after neoadjuvant chemotherapy. , 2013 .

[7]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Petra Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[9]  Stewart J Anderson,et al.  Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Woodward,et al.  Inflammatory breast cancer: what we know and what we need to learn. , 2012, The oncologist.

[11]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  B. Overmoyer.  Inflammatory breast cancer: novel preoperative therapies. , 2010, Clinical breast cancer.

[14]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[15]  W. Woodward,et al.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. , 2008, International journal of radiation oncology, biology, physics.

[16]  L. Jacobs,et al.  Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database , 2016, Journal of Cancer Research and Clinical Oncology.

[17]  C. Matsen.  Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy , 2016 .

[18]  D. Schultz,et al.  Ten-year outcome after combined modality therapy for inflammatory breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[19]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.